KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 108 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 4.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,329 | -29.0% | 5,434 | -33.7% | 0.00% | – |
| Q2 2023 | $73,728 | +3.1% | 8,192 | -10.0% | 0.00% | – |
| Q1 2023 | $71,526 | +8.3% | 9,100 | -6.9% | 0.00% | – |
| Q4 2022 | $66,052 | -52.8% | 9,771 | +1.1% | 0.00% | – |
| Q3 2022 | $140,000 | +35.9% | 9,661 | -7.7% | 0.00% | – |
| Q2 2022 | $103,000 | -27.5% | 10,467 | +8.7% | 0.00% | – |
| Q1 2022 | $142,000 | -12.9% | 9,631 | -21.7% | 0.00% | – |
| Q4 2021 | $163,000 | -12.8% | 12,298 | +14.6% | 0.00% | – |
| Q3 2021 | $187,000 | -71.5% | 10,733 | -60.8% | 0.00% | -100.0% |
| Q2 2021 | $657,000 | -11.0% | 27,415 | -4.6% | 0.00% | 0.0% |
| Q1 2021 | $738,000 | +76.1% | 28,739 | +30.2% | 0.00% | 0.0% |
| Q4 2020 | $419,000 | +63.0% | 22,080 | +8.2% | 0.00% | – |
| Q3 2020 | $257,000 | +8.4% | 20,406 | +4.4% | 0.00% | – |
| Q2 2020 | $237,000 | +58.0% | 19,546 | 0.0% | 0.00% | – |
| Q1 2020 | $150,000 | -56.4% | 19,546 | +1.2% | 0.00% | -100.0% |
| Q4 2019 | $344,000 | +65.4% | 19,321 | +7.5% | 0.00% | – |
| Q3 2019 | $208,000 | -47.7% | 17,971 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $398,000 | – | 17,971 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |